Poractant alpha
Newborn use only

2020

Alert	This medication should only be administered by a medical officer or nurse practitioner.
Indication	Treatment and prophylaxis of respiratory distress syndrome (RDS). Treatment of meconium aspiration syndrome (MAS).
Action	Lowers surface tension on alveolar surfaces during respiration and stabilises the alveoli against collapse at resting trans pulmonary pressures.
Drug type	Pulmonary surfactant
Trade name	Curosurf
Presentation	Suspension for intra-tracheal use 120mg/1.5mL or 240mg/3mL vials
Dose	**Respiratory distress syndrome** Loading dose of 200mg/kg Repeat dose of 100mg/kg when required every 6–12 hours. Maximum of 3 doses. **Meconium aspiration syndrome** Single dose: 200mg/kg Further doses can be given as below if required: 2nd dose: 200mg/kg 3rd dose: 100mg/kg 4th dose: 100mg/kg These doses can be administered at 6 hour interval.
Dose adjustment	Therapeutic hypothermia – Not applicable. ECMO – Not applicable Renal impairment – No dose adjustment. Hepatic impairment – No dose adjustment.
Maximum dose	
Total cumulative dose	
Route	Intra-tracheal
Preparation	Not applicable
Administration	This medication should only be administered by a medical officer or nurse practitioner. Inspect product visually for discolouration prior to administration (suspension should be white to creamy white). Before use, the vial should be slowly warmed to room temperature (can be warmed in hand or stood at room temperature) and gently turned upside down in order to obtain a uniform suspension. DO NOT SHAKE. Poractant alpha is administered via the endotracheal route using an endotracheal tube (ETT) or thin catheter. **ETT administration:** Assess patency and position of ETT prior to administration. Clear the trachea of secretions if required. Shorten a 5 French end-hole catheter so that the length of the catheter is 1 cm shorter than the ET tube. Slowly withdraw entire contents of vial(s) into a syringe through a needle (≥ 20 gauge). Do not shake. Attach shortened catheter to syringe. Fill catheter with surfactant. May administer in 1 to 2 aliquots as tolerated with the neonate in neutral supine position. If the infant is on a ventilator, the catheter can be inserted into the infant's ET tube without interrupting ventilation by passing the catheter through a neonatal suction valve attached to the ET tube. This is especially useful in high-frequency ventilation to minimise de-recruitment. Alternatively, surfactant can be instilled through the catheter by briefly disconnecting the ETT from the ventilator. Approximately 2 mL of air may be used to push any remaining surfactant in the catheter into the lungs. **Thin catheter administration:** Use a 4 French end-hole catheter marked approximately 1.5 cm above one end. Connect a syringe and catheter prefilled with surfactant preparation. While the infant is breathing via nasal CPAP, introduce laryngoscope and insert catheter using Magill forceps up to the mark on the catheter. Secure tube position and remove laryngoscope. With the infant's mouth closed, instil surfactant during 30 to 120 seconds by mini-boluses. In cases of apnoea or bradycardia, perform positive pressure ventilation until recovery.

Monitoring	Continuous oxygen saturation and cardiorespiratory monitoring.
Contraindications	None known
Precautions	Correction of acidosis, hypotension, anaemia, hypoglycaemia and hypothermia is recommended by the manufacturer prior to poractant alpha administration but this is not always possible in practice.
Drug interactions	Not applicable
Adverse reactions	Transient: Bradycardia, hypotension, endotracheal tube blockage and oxygen desaturation. These events require stopping poractant alpha administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring. Ventilator settings may need to be adjusted post-surfactant to accommodate increased lung compliance.
Compatibility	Should not be mixed with any other medications or fluids.
Incompatibility	Not applicable
Stability	Vials are for single use only. DO NOT SHAKE. Unopened, unused vials that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. Document on the packaging the date and time the product was removed from the fridge. Notify Pharmacy Department/NICU Pharmacist if this occurs. Do not warm to room temperature and return to refrigerated storage more than once.
Storage	Store at 2–8°C. Protect from light.
Excipients	
Special comments	Surfactant may alter amplitude-integrated electroencephalography (aEEG) recordings after administration.
Evidence	Refer to full version.
Practice points	Refer to full version.
References	Refer to full version.

VERSION/NUMBER	**DATE**
Original 1.0	**27/10/2015**
Current	10/12/2020
REVIEW	10/12/20205

Authors Contribution

Original author/s	Jing Xiao, Srinivas Bolisetty
Evidence Review	David Osborn
Expert review	
Nursing Review	Eszter Jozsa, Kirsty Minter
Pharmacy Review	Jing Xiao
ANMF Group contributors	Nilkant Phad, Bhavesh Mehta, John Sinn, Carmen Burman, Michelle Jenkins, Helen Huynh, Wendy Huynh, Thao Tran, Jessica Mehegan
Final editing and review of the original	Ian Whyte
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty